Journal of the American Academy of Dermatology
-
J. Am. Acad. Dermatol. · Feb 2020
Randomized Controlled TrialRuxolitinib cream for the treatment of patients with alopecia areata: A 2-part, double-blind, randomized, vehicle-controlled phase 2 study.
There are currently no treatments for alopecia areata (AA) that are universally effective or approved by the US Food and Drug Administration. Oral ruxolitinib has shown efficacy in extensive AA. Ruxolitinib cream would potentially avoid systemic adverse effects. ⋯ The 1.5% ruxolitinib cream did not have a significant effect in patients with AA.
-
J. Am. Acad. Dermatol. · Feb 2020
Randomized Controlled TrialLong-term efficacy and safety of brodalumab in the treatment of psoriasis: 120-week results from the randomized, double-blind, placebo- and active comparator-controlled phase 3 AMAGINE-2 trial.
Randomized controlled trials have shown the efficacy and safety of brodalumab in patients with moderate to severe plaque psoriasis. ⋯ Brodalumab is well tolerated and showed robust efficacy for more than 2 years.